Search

Glaxosmithkline Euro Medium Term Note Programme Prospectus Document 2014

Media

https://www.gsk.com/media/7913/glaxosmithkline-euro-medium-term-note-programme-prospectus-document-2014.pdf

First published: 31 May 2022

Glaxosmithkline Euro Medium Term Note Programme – Prospectus Document 2014

Media

https://www.gsk.com/media/8536/glaxosmithkline-euro-medium-term-note-programme-prospectus-document-2014.pdf

First published: 10 June 2022

GSK's Promacta® (eltrombopag) receives FDA approval of an additional indication

Media

New first-in-class treatment option for this previously treated SAA patient population

https://www.gsk.com/en-gb/media/press-releases/gsks-promacta-eltrombopag-receives-fda-approval-of-an-additional-indication/

First published: 26 August 2014

GlaxoSmithKline and Human Genome Sciences announce full presentation at ACR of positive phase 3 study results for Benlysta in systemic lupus erythematosus

Media

Benlysta (belimumab) significantly reduced SLE disease activity, disease flare rates and fatigue; delayed time-to-first SLE disease flare.

https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-human-genome-sciences-announce-full-presentation-at-acr-of-positive-phase-3-study-results-for-benlysta-in-systemic-lupus-erythematosus/

First published: 19 October 2009

Human Genome Sciences and GlaxoSmithKline announce positive Phase 3 study results for Benlysta™ in systemic lupus erythematosus

Media

GSK & HGS announced that Benlysta met the primary endpoint in BLISS-52, Phase 3 trials in patients with serologically active SLE.

https://www.gsk.com/en-gb/media/press-releases/human-genome-sciences-and-glaxosmithkline-announce-positive-phase-3-study-results-for-benlysta-in-systemic-lupus-erythematosus/

First published: 20 July 2009

$500,000 Endowment Gift from The GlaxoSmithKline Foundation Expands Program to Help Patients with Cancer and their Families at The Children’s Hospital of Philadelphia

Media

The Children’s Hospital of Philadelphia is proud to announce a $500,000 gift from the GSK Foundation.

https://www.gsk.com/en-gb/media/press-releases/500-000-endowment-gift-from-the-glaxosmithkline-foundation-expands-program-to-help-patients-with-cancer-and-their-families-at-the-children-s-hospital-of-philadelphia/

First published: 18 March 2013

GSK gains accelerated FDA approval for combination use of Mekinist® (trametinib) and Tafinlar® (dabrafenib)

Media

GSK announced today that the FDA has approved Mekinist® (trametinib) for use with Tafinlar® (dabrafenib) for the treatment melanoma

https://www.gsk.com/en-gb/media/press-releases/gsk-gains-accelerated-fda-approval-for-combination-use-of-mekinist-trametinib-and-tafinlar-dabrafenib/

First published: 09 January 2014

GSK and Genmab receive FDA approval for Arzerra

Media

GSK & GEN announced today that the FDA has approved a sBLA for Arzerra® (ofatumumab) for CLL

https://www.gsk.com/en-gb/media/press-releases/gsk-and-genmab-receive-fda-approval-for-arzerra/

First published: 17 April 2014

GSK achieves approval for Nucala (mepolizumab) for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) for adults in the US

Media

First targeted treatment approved for this rare eosinophil-driven disease

https://www.gsk.com/en-gb/media/press-releases/gsk-achieves-approval-for-nucala-mepolizumab-for-the-treatment-of-eosinophilic-granulomatosis-with-polyangiitis-egpa-for-adults-in-the-us/

First published: 12 December 2017

US FDA approves ViiV Healthcare’s Dovato (dolutegravir/lamivudine), the first, once-daily, single-tablet, two-drug regimen for treatment-naïve HIV-1 adults

Media

Dovato strengthens ViiV Healthcare’s industry-leading portfolio of innovative treatment approaches for people living with HIV.

https://www.gsk.com/en-gb/media/press-releases/us-fda-approves-viiv-healthcare-s-dovato-dolutegravirlamivudine-the-first-once-daily-single-tablet-two-drug-regimen-for-treatment-naïve-hiv-1-adults/

First published: 08 April 2019